## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 0 3 7006

In re Application of

ANDRE, et. al.

Examiner:

Blessing M. Fubara

Application No.:

10/019,588

Art Unit:

1618

Filed:

December 20, 2001

Title:

PHARMACEUTICAL DOSAGE FORMS

FOR CONTROLLED RELEASE PRODUCING AT LEAST A TIMED

**PULSE** 

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 3, 2006

Signature

EV527830711US

Express Mail No.

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination under §1.114 whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

	(b)	This	Information Disclosure Statement is filed after the period set forth in 37 C.F.R.				
		1.97(	b), but is believed to be filed before the mailing date of a final action under §1.113				
		or a r	notice of allowance under §1.311, whichever occurs first.				
		(1)	The undersigned attorney certifies that each item of information contained in this				
			Information Disclosure Statement was cited in a communication from a foreign				
			patent office in a counterpart foreign application not more than three months prior				
			to the filing of this statement;				
		(2)	The undersigned attorney certifies that no item of information contained in this				
			Information Disclosure Statement was cited in a communication from a foreign				
			patent office in a counterpart foreign application or, to the knowledge of the				
			undersigned attorney after making reasonable inquiry, was known to any				
			individual designated in §1.56(c) more than three months prior to the filing of this				
			statement; or				
		(3)	This Information Disclosure Statement is accompanied by a transmittal letter in				
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is				
			authorized.				
			D				
			Respectfully submitted,				
Ja	mu	asy	3, 2006 Balason Gyp.  Relevan Gunta Rag No 40,000				
		0	Balaram Gupta, Reg. No. 40,009				
			Attorney/Agent for Applicant				

Aventis Pharmaceuticals Inc.
(a member of the sanofi-aventis group)
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626
Aventis Docket No. SANSYL002 US PCT

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no per

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 Sheet 1 of

Complete if Known				
Application Number	10/019588	1		
Filing Date	06-27-2000	٦		
First Named Inventor	ANDRE, et. al.	- 20		
Group Art Unit	1615	7		
Examiner Name	SUSAN TRAN			
Attorney Docket Number	SANSYL002 - US - PCT			

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Number	Document Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		4,986,987		AYER, et. al.	01-22-1991	-	
		4,994,273		ZENTNER, et. al.	02-19-1991		
		5,176,901		GALLOPO, et. al.	01-05-1993		
		5,425,950		DANDIKER, et. al.	06-20-1995		
		5,494,681		CUCA, et. al.	02-27-1996		
		5,948,438		STANIFORTH, et. al.	09-07-1999	****	
		6,309,668		BASTIN, et. al.	10-30-2001		
		6,340,476		MIDHA, et. al.	01-22-2002		
		6,485,746		CAMPBELL, et. al.	11-26-2002		
		<u> </u>					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document  Kind Code <sup>5</sup> Office <sup>3</sup> Number <sup>4</sup> ( <i>if known</i> )			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		FR	2,656,303		NOUALHAC, 5% to.	06-28-1991		
		wo	96/41617		CONTE, et. al.	12-27-1996		
		GB	2,185,887		WAY. et 1.	08-05-1987		
					·			
								ļ
		ļ						
								+
		-			<u> </u>			+
		11111						

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.